Sign In
Buy LQDA
$55.69
+0.580 (+1.05%)
At Close: Jun 03, 2026
Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences
08:00am, Monday, 03'rd Nov 2025
MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseas
Liquidia Corporation (LQDA) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies Transcript
02:46pm, Wednesday, 29'th Oct 2025
Liquidia Corporation ( LQDA ) Discusses Innovations in Inhaled Treprostinil Therapies and Updates on Drug Delivery Technologies October 28, 2025 2:00 PM EDT Company Participants Roger Jeffs - CEO & Di
Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025
08:30am, Monday, 27'th Oct 2025
MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, an
Liquidia Technologies (NASDAQ:LQDA) vs. BioNTech (NASDAQ:BNTX) Financial Comparison
01:48am, Wednesday, 22'nd Oct 2025
BioNTech (NASDAQ: BNTX - Get Free Report) and Liquidia Technologies (NASDAQ: LQDA - Get Free Report) are both medical companies, but which is the better business? We will compare the two businesses ba
Wall Street Analysts Believe LIQUIDIA CORP (LQDA) Could Rally 50.94%: Here's is How to Trade
10:56am, Tuesday, 21'st Oct 2025
The consensus price target hints at a 50.9% upside potential for LIQUIDIA CORP (LQDA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings est
Liquidia Corporation to Host R&D Day in New York City on October 28, 2025
06:30am, Tuesday, 07'th Oct 2025
MORRISVILLE, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, to
Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference
08:30am, Wednesday, 27'th Aug 2025
MORRISVILLE, N.C., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that members of the company's executive leadership team will be providing an update on the com
Liquidia Analysts Raise Their Forecasts Following Q2 Results
02:51pm, Wednesday, 13'th Aug 2025
Liquidia Corporation LQDA reported a loss for the second quarter on Tuesday.
Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates
04:01pm, Tuesday, 12'th Aug 2025
Liquidia Technologies, Inc. (LQDA) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.37 per share a year ago.
Why Is Liquidia Stock Trading Higher On Tuesday?
02:25pm, Tuesday, 12'th Aug 2025
Liquidia Corporation LQDA reported on Tuesday a second-quarter loss of 49 cents, missing the consensus of a loss of 43 cents.
Liquidia Corporation (LQDA) Q2 2025 Earnings Call Transcript
12:43pm, Tuesday, 12'th Aug 2025
Liquidia Corporation (LQDA) Q2 2025 Earnings Call Transcript
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
06:30am, Tuesday, 12'th Aug 2025
MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases,
What Next For Liquidia After Launch?
10:40am, Monday, 30'th Jun 2025
Liquidia shipped its first FDA-approved product, Yutrepia for pulmonary hypertension in June entering market worth several billion dollars. Market sentiment remains skeptical, pricing in limited Yutre
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
04:34pm, Monday, 23'rd Jun 2025
MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, t
Liquidia price target lowered by $2 at BofA, here's why
01:19pm, Tuesday, 10'th Jun 2025
Liquidia -2.845 (-15.80%) Insmed +19.21 (+27.19%) 17 Jun
